Ulcerative Colitis Clinical Research Study

Let's Navigate Ulcerative Colitis Together

If life with ulcerative colitis feels like it revolves around constant planning, pain and uncertainty, explore a different route with the LATITUDE UC Study.

Did You Know?

UC most commonly develops in people aged 15 to 30 years old, but it can develop in people of any age.¹ That’s why researchers continue to seek effective treatment options for people of all ages.

UC symptoms can be mild, but more than 1 in 5 people have a moderate to severe case.² Researchers are looking for ways to help them.

Having UC can be stressful, and those with higher perceived stress levels have a greater chance of experiencing a flare.³

Flares can affect so much of daily life – outings with friends, what to eat, when to leave the house and much more. Evidence suggests that 87% of people with UC have an impaired quality of life.²

Over time, UC has become more common around the world,⁴ and in some locations, there has been an increase in the prevalence of UC in communities of colour.⁵ That’s why it’s important for people from all communities to be represented in clinical research.

Explore a different route for potential relief with the LATITUDE UC Study.

¹ https://pubmed.ncbi.nlm.nih.gov/30840605

² https://www.crohnscolitisfoundation.org/sites/default/files/2019-02/Updated%20IBD%20Factbook.pdf

³ https://pubmed.ncbi.nlm.nih.gov/10811330

⁴ https://doi.org/10.1016/j.jval.2018.04.556

⁵ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10210746

See If You May Qualify

You may be able to take part in the LATITUDE UC Study if you:

Are 18 to 75 years old

Were diagnosed with ulcerative colitis (UC) and are currently experiencing symptoms

Have tried at least one other treatment for your UC that didn't work

Are interested in an investigational oral treatment

About the LATITUDE UC Study

The LATITUDE UC Study is evaluating the efficacy and safety of an investigational oral treatment for ulcerative colitis (UC). Participants will receive the investigational treatment or a placebo (a substance that looks like the investigational treatment but does not contain any active ingredients) while completing various study tests and procedures.

Participants originally assigned to the placebo will have the opportunity to switch to the investigational treatment after the 12-week induction period. All study treatments will be given as oral pills.

Neither participants nor the study staff will know if participants are receiving the investigational treatment or a placebo. Participants will attend up to 14 scheduled study visits (and any additional study visits if needed) over the course of about a year.

Let's

navigate

Ulcerative Colitis

together